PRKAA1 and metabolic dysfunction-associated steatohepatitis: Given that lower dosing of metformin (50 mpk) failed to activate AMPK signaling, we focused our characterization of NASH measures on the group receiving the higher, yet still physiological (250 mpk) dose of metformin (38, 39).